Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade
Abstract The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. To date, analyses of tumor biopsies are the only pa...
Saved in:
Main Authors: | Yo-Ting Tsai, Jeffrey Schlom, Renee N. Donahue |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13046-024-02969-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non‐small cell lung cancer patients
by: Yidan Ma, et al.
Published: (2024-09-01) -
Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
by: Lova Sun, MD, MSCE, et al.
Published: (2025-01-01) -
Targeting HVEM-GPT2 axis: a novel approach to T cell activation and metabolic reprogramming in non-small cell lung cancer therapy
by: Yuanshan Yao, et al.
Published: (2025-02-01) -
Immune Checkpoint Blockade in Melanoma – Earlier is Better?
by: Vincas Urbonas, et al.
Published: (2024-09-01) -
CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer
by: Qian Dai, et al.
Published: (2024-12-01)